It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipid (CoPoP) liposomes decorated with repaired and stabilized clade C HIV-1 Env trimers in a prefusion conformation. These particles exhibit high HIV-1 Env trimer decoration, serum stability and bind broadly neutralizing antibodies. Three sequential immunizations of female rabbits with CoPoP liposomes displaying a different clade C HIV-1 gp140 trimer at each dosing generate high HIV-1 Env-specific antibody responses. Additionally, serum neutralization is detectable against 18 of 20 multiclade tier 2 HIV-1 strains. Furthermore, the peak antibody titers induced by CoPoP liposomes can be recalled by subsequent heterologous immunization with Ad26-encoded membrane-bound stabilized Env antigens. Hence, a CoPoP liposome-based HIV-1 vaccine that can generate cross-clade neutralizing antibody immunity could potentially be a component of an efficacious HIV-1 vaccine.
HIV vaccine candidates often have limited capacity to induce broadly neutralizing antibodies (nAbs). In this study, the authors show that stabilized Clade C HIV-1 Env protein trimers decorated on CoPoP liposomes induce nAbs against 18 of 20 multiclade tier 2 HIV-1 strains in immunized rabbits.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Strokappe, Nika M. 1
; Tolboom, Jeroen 1 ; Vreugdenhil, Jessica 1 ; Boer, Karin Feddes-de 1 ; Perkasa, Aditya 1 ; Blokland, Sven 1
; Burger, Judith A. 2 ; Huang, Wei-Chiao 3 ; Lovell, Jonathan F. 3 ; van Manen, Danielle 1 ; Sanders, Rogier W. 2
; Zahn, Roland C. 1
; Schuitemaker, Hanneke 1
; Langedijk, Johannes P. M. 4 ; Wegmann, Frank 1
1 Janssen Vaccines & Prevention, Leiden, The Netherlands (GRID:grid.497529.4) (ISNI:0000 0004 0625 7026)
2 University of Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Medical Microbiology, Amsterdam UMC, Amsterdam, the Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)
3 University at Buffalo, Department of Biomedical Engineering, Buffalo, USA (GRID:grid.273335.3) (ISNI:0000 0004 1936 9887)
4 Janssen Vaccines & Prevention, Leiden, The Netherlands (GRID:grid.497529.4) (ISNI:0000 0004 0625 7026); ForgeBio, Amsterdam, The Netherlands (GRID:grid.497529.4)




